AU2016279099B2 - Pharmaceutical composition of carboplatin based co-crystals and use thereof - Google Patents

Pharmaceutical composition of carboplatin based co-crystals and use thereof Download PDF

Info

Publication number
AU2016279099B2
AU2016279099B2 AU2016279099A AU2016279099A AU2016279099B2 AU 2016279099 B2 AU2016279099 B2 AU 2016279099B2 AU 2016279099 A AU2016279099 A AU 2016279099A AU 2016279099 A AU2016279099 A AU 2016279099A AU 2016279099 B2 AU2016279099 B2 AU 2016279099B2
Authority
AU
Australia
Prior art keywords
crystal
cancer
nmp
cbp
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016279099A
Other languages
English (en)
Other versions
AU2016279099A1 (en
Inventor
Xiaozhong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn Nat Products Enterprise LLC
Original Assignee
Syn Nat Products Enterprise LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn Nat Products Enterprise LLC filed Critical Syn Nat Products Enterprise LLC
Publication of AU2016279099A1 publication Critical patent/AU2016279099A1/en
Application granted granted Critical
Publication of AU2016279099B2 publication Critical patent/AU2016279099B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016279099A 2015-06-19 2016-06-20 Pharmaceutical composition of carboplatin based co-crystals and use thereof Ceased AU2016279099B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182142P 2015-06-19 2015-06-19
US62/182,142 2015-06-19
PCT/US2016/038340 WO2016205785A1 (en) 2015-06-19 2016-06-20 Pharmaceutical composition of carboplatin based co-crystals and use thereof

Publications (2)

Publication Number Publication Date
AU2016279099A1 AU2016279099A1 (en) 2018-01-04
AU2016279099B2 true AU2016279099B2 (en) 2021-09-23

Family

ID=57546414

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016279099A Ceased AU2016279099B2 (en) 2015-06-19 2016-06-20 Pharmaceutical composition of carboplatin based co-crystals and use thereof

Country Status (9)

Country Link
US (1) US10421770B2 (enExample)
EP (1) EP3297636B1 (enExample)
JP (1) JP6768716B2 (enExample)
KR (1) KR20180018800A (enExample)
CN (1) CN107847508B (enExample)
AU (1) AU2016279099B2 (enExample)
BR (1) BR112017027285A2 (enExample)
CA (1) CA2988992A1 (enExample)
WO (1) WO2016205785A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135877B (zh) * 2015-05-18 2021-04-13 新纳特产品公司 药物共晶及其用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1121380C (zh) 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
WO2003045962A1 (fr) * 2001-11-30 2003-06-05 Jingzun Wang Derives de carboplatine supramoleculaires, leur preparation, compositions pharmaceutiques les contenant comme ingredient actif et utilisations de ces compositions
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
ATE453653T1 (de) 2003-08-13 2010-01-15 Univ South Florida Platinkomplexe zur behandlung von tumoren
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
MX2007008810A (es) * 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
CN100500219C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种含铂类化合物的抗实体肿瘤药物组合物
RU2008135369A (ru) 2006-01-30 2010-03-10 Платко Текнолоджис (Проприэтэри) Лимитед (Za) Получение комплексов платины(ii)
PL2049109T3 (pl) 2006-08-02 2016-05-31 Sunesis Pharmaceuticals Inc Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
BRPI0808526A2 (pt) * 2007-03-02 2014-08-19 Novartis Ag Formas sólidas de um inibidor de raf cinase
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
KR100957125B1 (ko) * 2008-01-14 2010-05-11 한국과학기술원 생체 고분자와 난용성 물질의 접합체 및 그의 제조방법
AU2009290365B2 (en) 2008-09-15 2014-08-14 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
US9220705B2 (en) 2013-03-07 2015-12-29 James David Hoeschele Method of treating colorectal cancer
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
CN111638234B (zh) * 2014-08-13 2024-09-03 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN104127402B (zh) 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
CN104693245A (zh) * 2015-03-13 2015-06-10 卓越同达医药科技开发（苏州）有限公司 超分子抗癌药物双环铂的制备方法
WO2016164040A1 (en) 2015-04-10 2016-10-13 Syn-Nat Products Enterprise LLC Process for the preparation of dicycloplatin
US20180085377A1 (en) 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
CN108135877B (zh) 2015-05-18 2021-04-13 新纳特产品公司 药物共晶及其用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions

Also Published As

Publication number Publication date
CA2988992A1 (en) 2016-12-22
EP3297636B1 (en) 2021-02-17
EP3297636A1 (en) 2018-03-28
AU2016279099A1 (en) 2018-01-04
KR20180018800A (ko) 2018-02-21
CN107847508A (zh) 2018-03-27
US10421770B2 (en) 2019-09-24
WO2016205785A1 (en) 2016-12-22
JP6768716B2 (ja) 2020-10-14
BR112017027285A2 (pt) 2018-09-11
JP2018524320A (ja) 2018-08-30
CN107847508B (zh) 2020-10-02
EP3297636A4 (en) 2018-11-14
US20180179240A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US11685757B2 (en) Pharmaceutical co-crystal composition and use thereof
AU2017282871B2 (en) Crystalline forms of triazolopyrimidine compound
EP3297624B1 (en) A pharmaceutical co-crystal and use thereof
CA2854836C (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
AU2016279099B2 (en) Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN103191121B (zh) 二(喹唑啉-4-基)二硒醚化合物在制备抗癌药物中的用途
CN109384739B (zh) 一种可比司他新晶型及其制备方法
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired